A Phase 1b Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Subjects With Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability and to establish the maximum tolerated dose of JNJ-26481585 combined with VELCADE and dexamethasone.
100 项与 JNJ-2641585 相关的临床结果
100 项与 JNJ-2641585 相关的转化医学
100 项与 JNJ-2641585 相关的专利(医药)
100 项与 JNJ-2641585 相关的药物交易